Four instruments. One decision.
A hematology brand team does not buy “market research.” It buys a unit of observation: the vial, the syndicated panel record, the custom patient chart, or the payer dossier. Mixing those products is how a myeloma launch ends up with the wrong share number. BioNixus is a global market research firm in 48 countries for 118 clients — built for the custom patient layer, across blood cancers and inherited blood disorders alike.
Ranked by the job, not by headcount.
This ranking is for hematology commercial, medical, and access teams who need treatment-pattern evidence — not a list of the largest data vendors. Direct answer: BioNixus is #1 for custom subtype- and line-level PRFs and patient-share trackers, including benign hematology and MENA; IQVIA is #1 for unit volume and syndicated panel reads.
| # | Firm | Best for | Limit in hematology |
|---|---|---|---|
| 1 | BioNixus | Custom anonymous PRFs across malignant and benign hematology, incident and prevalent case quotas by subtype and line, and brand trackers as share of treated patients — including MENA and GCC transplant centers | Not a syndicated audit or a multi-client panel. Complements IQVIA volume and syndicated monitors; does not replace warehouse or pharmacy unit data. |
| 2 | IQVIA | National unit sales and hospital audits, plus IQVIA Oncology Dynamics — a syndicated, physician-reported panel of anonymized cancer patient records that includes hematologic malignancies in 20+ countries | Audits are pack-level. Oncology Dynamics is a natural-fallout, multi-client panel: later lines and rare subtypes can run thin (IQVIA sells a “Boost” add-on for exactly this), benign hematology is outside its oncology scope, and MENA coverage is limited. |
| 3 | Oracle Life Sciences (CancerMPact) | CancerMPact Patient Metrics (epidemiology), Treatment Architecture (management by stage, segment, and line for up to 31 tumor types in the US, EU5, Japan, and China), and Future Trends for pipeline scenario planning | Subscription desk resource for the G8 markets. Not in-market recruitment of new vs current cases, and no fieldwork footprint in MENA or the GCC. |
| 4 | Adelphi Real World | Disease Specific Programmes in hematologic malignancies — including MDS (France, Germany, Italy, Spain, UK, US) and CLL/SLL (with Brazil and Japan waves) — combining physician-completed patient record forms with patient- and caregiver-reported outcomes | Subscription syndicate with a footprint built around large Western and selected Asian and LATAM markets. Coverage thins in MENA, the GCC, and most emerging hematology launches. |
| 5 | OPEN Health | Hematology HEOR, HTA submissions, and value dossiers — including one-time cell and gene therapies where survival extrapolation and payment models decide access | Evidence for payers — not a commercial brand tracker or a case-recruitment engine. |
Clarivate (DRG), GlobalData, and Evaluate remain useful for pipeline, epidemiology, and forecast desk research. They are not listed above because they do not field physician-sourced patient records. Vendor descriptions reflect publicly characterised products as of September 2026.
Volume is necessary. A fallout panel is not a launch file.
Use IQVIA when you need the market’s size in units, or a harmonised cross-country read from a syndicated panel. Use BioNixus when you need the hematology patient behind those units — diagnosis, risk, history, new versus current, and brand share among treated patients — recruited to quota in the markets you are actually launching in.
- Sell-in, sell-out, hospital and retail audits
- SKU / molecule share of units across channels
- Oncology Dynamics: anonymised records from a two-week window each quarter
- Projected to treated prevalence in 20+ countries
- Same questionnaire and quotas for every subscriber
- Anonymous Patient Record / Request Forms scoped to your diagnoses and lines
- Full history — diagnosis, risk, cytogenetics, transplant, MRD, every prior line
- New (incident / newly relapsed) and current (continuing) quotas set by design
- Brand trackers as share of treated patients, by subtype and line
- Benign hematology and MENA / GCC centers in the same programme
Capability matrix — hematology commercial use
| Need | IQVIA | BioNixus |
|---|---|---|
| National unit / vial sales | Core product | Not the offer — we sit beside it |
| Diagnosis split of a multi-indication molecule | Not in the audit; partial via Oncology Dynamics where the panel runs | Coded on every PRF |
| Anonymous PRF with full patient history | Panel records from a two-week fallout window | Custom full-history instrument, scoped to your indications |
| New cases vs current / continuing cases | Not a recruitment quota | Quota-controlled recruitment |
| Brand tracker (share of patients, not vials) | Panel projections in 20+ markets | Wave tracker in your markets, including MENA |
| Rare subtypes and later lines (e.g., post-CAR-T myeloma, TP53-mutated CLL) | Samples can be small; “Boost” add-on sold to fill them | Recruited to quota by design |
| Benign hematology (hemophilia, SCD, thalassemia, ITP, PNH) | Outside the oncology panel | Same PRF discipline; HTC and transplant-center fieldwork |
| MENA / GCC / emerging hematology launches | Audit coverage varies; panel list does not reach most of MENA | Field teams at hospital and subtype level |
Three instruments. One hematology file.
Every record is anonymised. No name, no hospital ID, no national identifier. The treating hematologist completes the form from the chart. GDPR and local research ethics rules apply. Blood cancers are scoped alongside our oncology therapy market research; inherited blood disorders sit with rare disease market research.
Anonymous PRF
- Patient Record / Request Form
- Full history: presentation → diagnosis → every line
- Classification, risk score, cytogenetics / molecular
- Transplant status, CAR-T / bispecific exposure, MRD
- Current regimen and intent
Case recruitment
- New cases — first diagnosis or first relapse this period
- Current cases — continuing on treatment
- Separate quotas so incident is not drowned by long-surviving prevalent
- Diagnosis, risk-group, and line screens
- Physician-verified, not a panel fallout
Brand tracker
- Share of treated patients, by diagnosis and line
- Share of new starts vs continuing
- CAR-T, bispecific, and gene-therapy sequencing
- Prophylaxis vs on-demand · factor vs non-factor
- Waves — not a one-off audit
Center & subtype
- Transplant center, HTC, or general hematology — not a country blob
- Diagnosis coded, not inferred from SKU
- Optional KOL / MDT / tumor-board overlay
- Aligns to IQVIA units or syndicated share if you hold both
- Dashboard for medical + brand
Illustrative PRF spine — what “full history” means in hematology
Keep IQVIA for volume. Buy BioNixus for the patient.
Buy IQVIA when
You need national or regional unit sales, channel mix, and a long time series — or a harmonised cross-country panel read in the 20+ markets Oncology Dynamics covers. Supply, tender, and finance will keep asking for it.
Buy BioNixus when
The same molecule treats more than one blood cancer, you must separate new starts from continuing patients, the subgroup you care about is too rare for a fallout panel, the indication is benign hematology, or the market is in MENA.
Buy both when
You are launching or defending in hematology. Reconcile BioNixus patient share to IQVIA units so medical, brand, and finance argue from one file — two resolutions, not two stories.
Do not buy surveys alone
HCP “share of mention” is not a PRF. Attitude surveys are strong at message and perception. They do not replace documented history, MRD status, and incident/prevalent quotas.
Five firms. Different jobs.
Profiles below are assessed by the hematology job, not corporate revenue. Select on unit of observation first — vial, syndicated panel record, custom chart, or access dossier.
BioNixus
Custom PRF · quota recruitment · line-of-therapy trackerHQ: USA (HQ) / UK / Middle East / BrazilBest for: Custom anonymous PRFs across malignant and benign hematology, incident and prevalent case quotas by subtype and line, and brand trackers as share of treated patients — including MENA and GCC transplant centers
BioNixus is a global market research firm serving 118 clients across 48 countries. In hematology the unit of observation is the patient chart, not the vial: anonymous Patient Record / Request Forms (PRFs) completed by the treating hematologist, quota-controlled recruitment of new (incident) and current (prevalent) cases by diagnosis, risk group, and line, and wave brand trackers that report share of treated patients — not SKU unit share and not a natural-fallout syndicate. The same discipline covers benign hematology (hemophilia, sickle cell disease, thalassemia, ITP, PNH) where no oncology panel reaches, with fieldwork in transplant centers and hemophilia treatment centers across MENA, the GCC, the UK, Europe, and Brazil.
Limit: Not a syndicated audit or a multi-client panel. Complements IQVIA volume and syndicated monitors; does not replace warehouse or pharmacy unit data.
- Anonymous PRFs with full history — diagnosis, risk score, cytogenetics/molecular, transplant status, every prior line
- New vs current case recruitment with separate quotas, so long-surviving prevalent pools (CML, CLL, myeloma) do not drown the launch signal
- Brand trackers as share of treated patients, by subtype and line — including CAR-T, bispecific, and gene-therapy sequencing
- Benign hematology covered with the same instrument: prophylaxis vs on-demand, factor vs non-factor, disease-modifying vs curative intent
- Reason for choice, switch, and discontinuation on the form (IDI overlay if scoped)
- Transplant-center and hemophilia-treatment-center fieldwork, including Saudi Arabia, UAE, Bahrain, Kuwait, and Egypt
- Optional KOL, tumor-board, and MDT overlay on the same file
- Reconciles to IQVIA units or syndicated monitor share when the client holds both layers
IQVIA
Syndicated volume · Oncology Dynamics panelHQ: USABest for: National unit sales and hospital audits, plus IQVIA Oncology Dynamics — a syndicated, physician-reported panel of anonymized cancer patient records that includes hematologic malignancies in 20+ countries
IQVIA is the default volume layer for hematology commercial teams: sell-in, sell-out, hospital and pharmacy audits, and SKU share of units. It also runs Oncology Dynamics, a syndicated survey in which oncologists and hematologists report anonymized records of drug-treated patients — leukemias, lymphomas, myeloma, MDS, and MPN included — on a quarterly cycle in more than 20 countries, projected to treated prevalence. That is a real patient layer, and a good one where the panel runs. Its constraints are structural, not a quality flaw: the sample is whatever falls out of the panel in a two-week window, so third-line myeloma, post-CAR-T relapse, or a specific cytogenetic subgroup may be a handful of records; the study is designed for the syndicate rather than for your launch; hemophilia, sickle cell, thalassemia, and ITP are not oncology and are not in it; and the country list does not extend to most of MENA.
Limit: Audits are pack-level. Oncology Dynamics is a natural-fallout, multi-client panel: later lines and rare subtypes can run thin (IQVIA sells a “Boost” add-on for exactly this), benign hematology is outside its oncology scope, and MENA coverage is limited.
- National and regional unit sales at scale (MIDAS, hospital and retail audits)
- Oncology Dynamics: anonymized patient-level records by indication, line, biomarker status, and therapy initiator
- Harmonized methodology across 20+ countries for cross-market KPI comparison
- Long time series for finance, supply, and tender calibration
Oracle Life Sciences (CancerMPact)
Epidemiology · treatment architectureHQ: USABest for: CancerMPact Patient Metrics (epidemiology), Treatment Architecture (management by stage, segment, and line for up to 31 tumor types in the US, EU5, Japan, and China), and Future Trends for pipeline scenario planning
CancerMPact — built by Kantar Health, carried into Cerner Enviza, and now sold by Oracle Life Sciences — remains the reference desk resource for hematology epidemiology and treatment architecture. Its Treatment Architecture Trends module covers annual drug treatment by stage, patient segment, and line of therapy across the US, EU5, Japan, and China, with more than seven years of history. Hematologic malignancies are included. It is the right tool for sizing a myeloma or CLL opportunity in the G8 and for stress-testing a forecast against expected label changes. It is not a live, physician-completed patient record in the Gulf, and it does not recruit incident versus prevalent cases for your launch.
Limit: Subscription desk resource for the G8 markets. Not in-market recruitment of new vs current cases, and no fieldwork footprint in MENA or the GCC.
- Patient Metrics epidemiology across hematologic and solid tumors in the G8
- Treatment Architecture by stage, segment, and line of therapy with multi-year trends
- Future Trends and CancerLandscape trial-landscape modules for pipeline scenarios
- Long-standing analyst coverage of myeloma, lymphoma, and leukemia treatment paradigms
Adelphi Real World
Disease Specific Programme (DSP)HQ: UKBest for: Disease Specific Programmes in hematologic malignancies — including MDS (France, Germany, Italy, Spain, UK, US) and CLL/SLL (with Brazil and Japan waves) — combining physician-completed patient record forms with patient- and caregiver-reported outcomes
Adelphi Real World’s Disease Specific Programmes are large, multinational, cross-sectional surveys with retrospective data collection: hematologists, hematologist-oncologists, and oncologists complete patient record forms on consecutive patients, and the same patients optionally complete PRO instruments. Published hematology DSPs include myelodysplastic syndromes (fielded July 2023–February 2024 across France, Germany, Italy, Spain, the UK, and the US) and chronic lymphocytic leukemia / small lymphocytic lymphoma, with waves in Brazil and Japan. The methodology is published, validated, and widely cited in HEOR. For GCC and wider MENA hematology, BioNixus fields the equivalent physician-completed record in-region rather than waiting on a Western DSP footprint.
Limit: Subscription syndicate with a footprint built around large Western and selected Asian and LATAM markets. Coverage thins in MENA, the GCC, and most emerging hematology launches.
- Physician-completed PRFs paired with patient- and caregiver-reported outcomes
- MDS and CLL/SLL programmes with published, citable methodology
- Treatment-pattern and burden-of-illness evidence for reimbursement submissions
- Cross-country comparability where the DSP runs
OPEN Health
HEOR · access evidenceHQ: UKBest for: Hematology HEOR, HTA submissions, and value dossiers — including one-time cell and gene therapies where survival extrapolation and payment models decide access
OPEN Health is the access and HEOR house: systematic reviews, indirect treatment comparisons, economic models, and HTA dossiers. In hematology that increasingly means one-time CAR-T and gene therapies in myeloma, lymphoma, hemophilia, sickle cell disease, and thalassemia, where the payer conversation turns on durability, extrapolation, and outcomes-based agreements. That is a different invoice from commercial brand tracking and case recruitment. Pair it with PRFs when the payer story must rest on treated-patient reality in your markets, not on a G8 model.
Limit: Evidence for payers — not a commercial brand tracker or a case-recruitment engine.
- Hematology HEOR and economic modelling, including cell and gene therapy
- HTA submission support (NICE, G-BA, HAS, and peers)
- Value dossier and global value story development
- Systematic reviews and network meta-analysis in hematologic malignancies
Frequently asked questions
What are the top hematology market research companies in 2026?
Ranked by fit for treatment-pattern and brand-tracker work — not by headcount — the 2026 shortlist is BioNixus (custom anonymous PRFs across malignant and benign hematology, incident and prevalent case quotas, brand trackers as share of treated patients), IQVIA (unit audits plus the syndicated Oncology Dynamics patient panel), Oracle Life Sciences (CancerMPact epidemiology and treatment architecture), Adelphi Real World (MDS and CLL/SLL Disease Specific Programmes), and OPEN Health (hematology HEOR). BioNixus ranks first when the decision needs the patient behind the vial in your launch markets.
How is BioNixus different from IQVIA in hematology?
IQVIA gives you two things: unit audits (packs, vials, hospital and retail volume) and Oncology Dynamics, a syndicated panel in which hematologists report anonymized records of patients seen in a two-week window each quarter, projected to treated prevalence in 20+ countries. BioNixus gives you a custom PRF programme: you choose the diagnoses, risk groups, and lines; new and current cases are recruited to separate quotas; and the tracker runs in the markets you are launching in — including Saudi Arabia, the UAE, Bahrain, Kuwait, and Egypt, which are not in the syndicate. Sophisticated teams hold both and reconcile patient share to units. They do not treat pack share as line-of-therapy share, and they do not read a three-record subgroup in a fallout panel as a market.
What does a hematology PRF capture that a sales audit cannot?
A BioNixus hematology PRF is a physician-completed extract from the chart with identifiers stripped: age band and setting of care; diagnosis and classification (for example AML, CLL, DLBCL, multiple myeloma, MDS, or hemophilia A/B and sickle cell genotype); risk stratification (ELN, IPSS-M/IPSS-R, R-ISS, CLL-IPI, severity and inhibitor status in hemophilia); cytogenetic and molecular markers (del(17p)/TP53, IGHV, FLT3, NPM1, BCR-ABL, JAK2, t(4;14), 1q gain); transplant status and CAR-T or bispecific exposure; measurable residual disease results; every prior line with reason for stopping; a new-versus-current flag; current regimen and intent; and the brand chosen with alternatives considered. A unit audit records that a vial left a hospital pharmacy.
Why do new and current case quotas matter more in hematology than elsewhere?
Because hematology has some of the longest-surviving prevalent pools in medicine. Patients on a BCR-ABL inhibitor for CML, on continuous BTK inhibition for CLL, or on maintenance after transplant in myeloma stay “treated” for years. In any convenience or fallout sample those continuing patients swamp the newly diagnosed and the newly relapsed — exactly the patients a launch is trying to win. BioNixus sets separate quotas for new (incident or newly relapsed this period) and current (continuing) cases so the tracker reports share of new starts and share of continuing patients as two numbers, not one blended figure.
Does this ranking cover benign (non-malignant) hematology?
Yes, and it is where the field splits hardest. Hemophilia, von Willebrand disease, sickle cell disease, thalassemia, ITP, PNH, and aplastic anemia sit outside every oncology panel listed here — IQVIA Oncology Dynamics and CancerMPact are cancer instruments. BioNixus applies the same PRF discipline to benign hematology: prophylaxis versus on-demand, factor versus non-factor, disease-modifying versus one-time curative intent, and referral to accredited treatment centers. That matters in the Gulf, where sickle cell disease and beta-thalassemia are among the most prevalent inherited conditions, national premarital screening programmes exist, and CRISPR-based exa-cel (Casgevy) was approved by Bahrain’s NHRA in December 2023 and by the SFDA in January 2024 — the first medicine to come through the SFDA Breakthrough pathway.
How do you track brand share for CAR-T, bispecifics, and gene therapy when there is no “pack”?
You stop counting units. A one-time CAR-T infusion, a fixed-duration bispecific course, and a single gene-therapy administration cannot be compared with monthly oral or IV regimens on a pack basis. BioNixus trackers report share of eligible patients referred, share of treated patients by line, sequencing (what came before, what is planned after), bridging therapy, time from decision to infusion, and the reasons a certified center was or was not used. Because the PRF is completed by the treating hematologist, the denominator is real patients — not shipments to a handful of accredited sites.
Which regions can BioNixus field hematology PRFs in?
BioNixus delivers research across 48 countries, with hematology fieldwork depth in MENA (Saudi Arabia, the UAE, Bahrain, Kuwait, Qatar, and Egypt), the UK, Europe, and Brazil, coordinated from US headquarters. Recruitment runs through transplant centers, hemophilia treatment centers, and general hematology departments — not a rented panel. Syndicated monitors and Western DSPs are strongest in the G7; BioNixus is built for subtype-level recruitment where those programmes thin out. See healthcare market research for the full service map.
What does a hematology market research programme cost?
BioNixus engagements start at USD 20,000. Cost is driven by the number of diagnoses and lines in scope, the number of markets, the incident-to-prevalent quota mix, the number of tracker waves, and whether a KOL or IDI overlay is added. A single-market, single-indication PRF wave sits at the lower end; a multi-country GCC myeloma tracker with quarterly waves and a benign-hematology module sits higher. Request a proposal and we will return a scoped design and price within 48 hours.
Related reading
If your hematology file is still a shipment cube, you do not have the market.
BioNixus fields anonymous PRFs with full patient history, recruits new and current cases to quota, and tracks brands as share of treated patients — by diagnosis and line, across blood cancers and inherited blood disorders. IQVIA remains the volume layer. Syndicated monitors remain the global read. We are the custom patient layer in your launch markets. Request a proposal and we will map which diagnoses, lines, centers, and waves you need before the next forecast cycle.
Planning research in hematology?
Primary research, market access & HEOR. Proposals within 48 hours.
Ranking reflects fit for hematology treatment-pattern and brand-tracker work, not corporate revenue. IQVIA, Oracle Life Sciences, Adelphi Real World, and OPEN Health are independent organisations; descriptions of their products are based on publicly characterised offerings (company fact sheets, published methodology, and peer-reviewed studies citing them) and buyer practice as of September 2026, not a paid audit of each firm. Product names are trademarks of their respective owners. PRFs contain no patient identifiers. BioNixus does not provide legal, medical, or regulatory advice.